Literature DB >> 12950018

Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.

Tatjana Crnogorac-Jurcevic1, Edoardo Missiaglia, Ekaterina Blaveri, Rathi Gangeswaran, Melanie Jones, Benoit Terris, Eithne Costello, John P Neoptolemos, Nicholas R Lemoine.   

Abstract

In order to expand our understanding of the molecular changes underlying the complex pathology of pancreatic malignancy, global gene expression profiling of pancreatic adenocarcinoma compared with normal pancreatic tissue was performed. Human cDNA arrays comprising 9932 elements were interrogated with fluorescence-labelled normal and adenocarcinoma samples (nine tumours, three normal pancreata, and three cell lines). The data were analysed for differential gene expression, which was confirmed by serial analysis of gene expression (SAGE), digital differential display (DDD) analysis, and immunohistochemistry for selected cases. The array data were filtered to produce lists of a total of 75 genes significantly up-regulated or down-regulated in pancreatic adenocarcinoma. Two of those showing the highest differential were members of the S100 family of Ca-binding proteins, namely S100P and S100A6, and therefore the S100 genes were studied in more detail. By immunohistochemical analysis of custom-built, pancreas-specific tissue arrays and commercially available, normal/cancer tissue arrays that included a wide variety of different tumour types, differential expression of S100P protein was found to be almost exclusive to pancreatic cancer. S100P could therefore represent a useful biomarker for pancreatic adenocarcinomas. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950018     DOI: 10.1002/path.1418

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  55 in total

1.  NMR structure of the Apo-S100P protein.

Authors:  Yi-Chien Lee; David E Volk; Varatharasa Thiviyanathan; Quinn Kleerekoper; Alexey V Gribenko; Shanmin Zhang; David G Gorenstein; George I Makhatadze; Bruce A Luxon
Journal:  J Biomol NMR       Date:  2004-07       Impact factor: 2.835

2.  Heterodimeric interaction and interfaces of S100A1 and S100P.

Authors:  Guozheng Wang; Shu Zhang; David G Fernig; David Spiller; Marisa Martin-Fernandez; Hongmei Zhang; Yi Ding; Zihe Rao; Philip S Rudland; Roger Barraclough
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

3.  Identification of cancer genomic markers via integrative sparse boosting.

Authors:  Yuan Huang; Jian Huang; Ben-Chang Shia; Shuangge Ma
Journal:  Biostatistics       Date:  2011-10-31       Impact factor: 5.899

Review 4.  S100P: a novel therapeutic target for cancer.

Authors:  Thiruvengadam Arumugam; Craig D Logsdon
Journal:  Amino Acids       Date:  2010-05-28       Impact factor: 3.520

5.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

6.  New tumor-associated antigen SC6 in pancreatic cancer.

Authors:  Min-Pei Liu; Xiao-Zhong Guo; Jian-Hua Xu; Di Wang; Hong-Yu Li; Zhong-Min Cui; Jia-Jun Zhao; Li-Nan Ren
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

7.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

8.  Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Craig D Logsdon
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

9.  Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics.

Authors:  Shu-Qin Jia; Zhao-Jian Niu; Lian-Hai Zhang; Xi-Yao Zhong; Tao Shi; Hong Du; Gui-Guo Zhang; Ying Hu; Xiu-Lan Su; Jia-Fu Ji
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-01       Impact factor: 4.553

Review 10.  High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma.

Authors:  S S Liau; E Whang
Journal:  Surgeon       Date:  2009-10       Impact factor: 2.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.